Table 3.

Proportion of patients^* with ≥1 statin prescription during one year from index date for all cohorts, general and stratified by covariables

	SLE	DM	General Medicaid
Cohort size (N)	25,950	51,900	103,800
General	2,777 (11%)	17,045 (33%)	6,926 (7%)
Sex
Female	11%	33%	7%
Male	12%	31%	7%
Age
18–39	7%	24%	1%
40–49	10%	38%	7%
50–65	17%	43%	15%
Outpatient Visits†
High	14%	39%	8%
Low	7%	23%	4%
Race/ethnicity
White	11%	31%	7%
Black	10%	29%	7%
Hispanic	11%	40%	4%
Asian	16%	51%	9%
American Indian/Alaskan Native	6%	29%	5%
U.S. Region of residence
West	11%	37%	4%
Northeast	12%	38%	8%
South	10%	29%	8%
Midwest	12%	31%	8%
SES Quartile
1st	11%	33%	8%
2nd	10%	32%	7%
3rd	11%	33%	6%
4th	11%	34%	6%
Lupus nephritis/Diabetic nephropathy	17%	35%
Cardiovascular disease (CVD)
Present	22%	44%	30%
Not present	9%	31%	6%
# Medications†
High	18%	49%	12%
Low	4%	19%	2%
Charlson comorbidity index†
High	14%	34%	14%
Low	8%	32%	5%
Glucocorticoid Use ≥10 mg/day ever
Yes	15%	42%	15%
No	8%	32%	6%

^*Proportion described as percentage of patients with variable in cohort who received statin prescription at one year (i.e., 11% of females in the SLE cohort received statin prescription at one year).

^†High: Equal to and higher than median; Low: Lower than median

Abbreviations: SLE, systemic lupus erythematosus; DM, diabetes mellitus; CVD, cardiovascular disease